Vibe Bio

Every cure for every community. Join us.

[Vibe Bio @VibeBio]

Today, we’re officially launching with $12 million in funding, two partnerships with patient advocacy organizations, and a growing community ready to build a new way to pursue cures to rare diseases https://t.co/plfGYEd4hA

[Vibe Bio @VibeBio]

Collaboration drives progress.

See how the Orphan Therapeutics Accelerator used Vibe Bio’s AI to rapidly assess and prioritize promising rare disease assets.

Read this case study to learn more →
https://t.co/Ruf7MZ51LX
#raredisease #casestudy #biotech #AI

[Vibe Bio @VibeBio]

When time is short, you need clarity. Vibe Bio’s AI, @incitedotorg was able to build & pursue a defensible shortlist in weeks — not months — balancing IP, manufacturability, safety, and route.

Dive deeper: https://t.co/lKlDLZx5ac

#DrugDev #AI #RareDisease #Biotech #casestudy

[Vibe Bio @VibeBio]

Knowledge silos, churned teams, conflicting decks — these are the killers of good BD decisions. AI can stitch together memory and context to help your team move fast and smart.
More here:
https://t.co/GE37Cf6xhB
#Biotech #AI #BusinessDevelopment

[Vibe Bio @VibeBio]

Vibe Bio partnered with the Orphan Therapeutics Accelerator to help accelerate rare disease drug search & evaluation — turning complexity into clarity with AI.

Learn more in this case study →
https://t.co/8dso8QUQOi
#raredisease #casestudy #biotech #AI

[Vibe Bio @VibeBio]

“Humans might take six months … and still miss opportunities.” AI helped @incitedotorg re-rank assets quickly, eliminating poor fits and adding new ones, and avoid bias in rare disease diligence.

Story here ➝
https://t.co/cM0GMg7zkh

#RareDisease #AI #Biotech #casestudy

[Vibe Bio @VibeBio]

BD teams in biopharma can’t afford to forget their past. AI lets you build a memory layer so you don’t re-evaluate the same assets, duplicate outreach, or miss red flags. Read why:
🔗 https://t.co/3kSwh7Ikf4
#Biotech #AI #BusinessDevelopment

[Vibe Bio @VibeBio]

How can rare disease teams move faster and smarter?
The Orphan Therapeutics Accelerator partnered with Vibe Bio to apply AI-driven evaluation and prioritize assets with the greatest potential.
Read the case study →
https://t.co/rjfWjobjZP
#raredisease #casestudy #biotech #

[Vibe Bio @VibeBio]

.@incitedotorg needed prioritized compounds in liposarcoma fast. With Vibe Bio’s AI, they built a defensible shortlist in weeks — not months — balancing IP, manufacturability, safety, and route.

Learn more now:
https://t.co/QOpWuYQ4P5

#RareDisease #AI #Biotech #casestudy

[PRV Watch @PRVWatch]

Stealth receives accelerated approval for elamipretide in Barth Syndrome and with it a priority review voucher. Third attempt at approval and the priority review voucher likely saves the company.

[Daphne Zohar @daphnezohar]

At the #StatusList dinner last night I was asked what I would change about our industry. My response: the likelihood of making it from discovery to FDA approval is ~1% & takes 10-15 yrs yet the incentives focus only on rewarding the successes w/ so much waste & lost knowledge. We need to find mechanisms to better share & recognize the learnings from the failures, whether they relate to clinical design/execution errors or learnings for a class of targets. What is one thing you would change about our industry?

[Vibe Bio @VibeBio]

“Memory is strategy in biopharma BD.”
When your team forgets the past, you repeat work, get mixed messages externally, and lose momentum. AI can keep your institutional knowledge alive.

🔗 https://t.co/C13Ia2lSyF
#Biotech #AI #BusinessDevelopment

[Vibe Bio @VibeBio]

Pipeline strategy shouldn’t depend on gut feel.
AI brings clarity, speed & competitive insight to portfolio decisions.
Full blog 👉 https://t.co/ggNPYSWFAz

#Biopharma #AI #PortfolioStrategy

[Vibe Bio @VibeBio]

In Kyoto 🇯🇵 — CEO & Co-Founder, @aloktayi, PhD, will be part of the STS Forum 2025 panel discussion about AI in healthcare.
October 6, 2025 (Monday) 10:40-12:40 (120 min).
Session Room B-1.
Excited to learn and contribute.
🔗 https://t.co/zfjLkD7sIf
#STSForum #AI #biotech

[Vibe Bio @VibeBio]

CEO & Co-Founder, @aloktayi, PhD, will be part of a panel on about AI in healthcare and how it can drive a healthier, more resilient future.
Join him and other world leaders at the STS Forum 2025 in Kyoto on October 6, 2025 10:40-12:40 (120 min).
👉 https://t.co/g26DkS7Yio

[Merck @Merck]

We are shaping the future of oncology with one of the largest clinical development programs in the industry. We’re focused on expanding into new tumor types and extending into earlier lines of disease. Learn more about where we’re focusing our oncology research efforts.

[Vibe Bio @VibeBio]

Check out our latest post, with insights about biopharma, artificial intelligence, and some travel pics from the team. https://t.co/uPQdDcW5wg #biopharma #AI #cats_of_world

[Vibe Bio @VibeBio]

Every portfolio decision is a bet.
But what if you could de-risk it with AI-powered analysis?
Learn more:
✅ How AI cuts through data noise
✅ Why human bias limits outcomes
✅ What better decisions mean for patients & pipelines
Read how:
https://t.co/vTLMsomOAK

[Vibe Bio @VibeBio]

Genomics is reshaping heart health. On #WorldHeartDay, Vibe Bio highlights how data-driven science leads to new hope for rare cardiovascular diseases. #Innovation #HeartHealth

[Vibe Bio @VibeBio]

📅 Today's the day! Register now to join us at 1 PM ET to get a practical, executive-level framework to evaluate AI solutions for BD&L teams. You’ll learn:
📷 Which features matter most
📷 A framework to evaluate vendors
📷 #biopharma
https://t.co/e852Fwy8K7
#AI #bizdev

[Vibe Bio @VibeBio]

📅 Join us tomorrow, September 24 at 1 PM ET to get a practical, executive-level framework to evaluate AI solutions for BD&L teams. You’ll learn:
🔍 Which features matter most
📊 How to measure ROI
🛠 A framework to evaluate vendors

👉 https://t.co/uDadc8augM
#biopharma